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ABSTRACT 
Background:   Digoxin is recommended in symptomatic heart failure patients with reduced 
ejection fraction (HF-REF) in sinus rhythm and refractory to other evidence-based therapy. 
Although HF-REF patients with diabetes have worse functional status than those without, the 
effects of digoxin have not been specifically evaluated according to diabetes status.  
 
Methods:   We examined the efficacy and safety of digoxin in HF-REF patients with and 
without diabetes in the Digitalis Investigation Group trial. Mortality from all-cause, 
cardiovascular (CV) causes and heart failure (HF), along with HF hospitalisation and 
suspected digoxin toxicity were analyzed according to diabetes status and randomised 
treatment assignment.  
 
Results: Of the 6800 patients, those with diabetes (n=1933) were older, more often women, 
had worse clinical status and more co-morbidity than those without diabetes. All-cause and 
CV mortality were higher in patients with diabetes than in those without and digoxin did not 
reduce mortality in either sub-group. The rate of HF hospitalisation (per 100 person-years) in 
patients with diabetes was higher than in those without and was reduced by digoxin in both 
patient groups: diabetes - placebo 20.5 and digoxin 16.0 (HR 0.79, 95%CI: 0.68-0.91); no 
diabetes - placebo 12.7 and digoxin 8.7 (HR 0.69, 0.62-0.77); interaction p=0.14. Suspected 
digoxin toxicity in patients randomised to digoxin was more common among patients with 
diabetes than without (6.5% versus 5.8%), as was hospitalisation for digoxin toxicity (1.4% 
versus 0.8%). 
 
Conclusion:   Added to an ACE inhibitor, digoxin reduced HF hospitalisation in HF-REF 
patients with and without diabetes without a substantial risk of toxicity. 
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1. INTRODUCTION 
Heart failure patients with diabetes have more co-morbidity and worse functional status than 
without diabetes.1-5 Patients with diabetes also have much higher rates of adverse 
cardiovascular outcomes. 1-5 Consequently, there is a particular need for treatments that 
improve symptoms, functional capacity and morbidity/mortality outcomes in heart failure 
patients with diabetes. 
 
Although digoxin is the oldest of currently recommended therapies for heart failure, its 
effects in patients with diabetes have never been described.  This omission is important as 
digoxin is often reserved for patients with worse heart failure status and such patients are 
more likely to have diabetes (as outlined above).6,7  Patients with diabetes are also more likely 
than those without to have renal dysfunction, potentially increasing the risk of digoxin 
toxicity. 1-5 We have, therefore, examined the efficacy and safety of digoxin in heart failure 
patients with and without diabetes randomised in the Digitalis Investigation Group trial 
(DIG).8.9  
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2. METHODS 
2.1. DIG inclusion and exclusion criteria  
The rationale, design and results of DIG have been published.8, 9 Patients were randomised at 
302 clinical centers in the United States and Canada. The study was approved by the ethics 
committee at each participating center and all patients gave written informed consent. 
Patients were eligible if they had heart failure and a left ventricular ejection fraction (LVEF) 
of 45% or less and were in sinus rhythm. The diagnosis of heart failure was based on current 
or past clinical symptoms (limitation of activity, fatigue, and dyspnoea or orthopnoea), signs 
(edema, elevated jugular venous pressure, rales, or a gallop rhythm), or radiologic evidence 
of pulmonary congestion. Exclusion criteria included a serum potassium below 3.2 mmol/l or 
above 5.5 mmol/l and significant renal insufficiency (creatinine greater than 3.0 mg/dl) or 
severe liver disease. Investigators were strongly encouraged to give study patients an 
angiotensin-converting–enzyme inhibitor. 
 
2.2. Study drug randomization and dosing and trial outcomes 
Patients were randomly assigned to receive digoxin or placebo. The initial dose of study drug 
was determined using an algorithm which took account of patient age, sex, weight, and renal 
function.8 Investigators were permitted to modify dose of study drug based on other factors, such 
as use of concomitant drugs that might alter digoxin pharmacokinetics.  
Follow-up visits took place at 4 weeks and 16 weeks after randomisation and every 4 months 
thereafter. The primary outcome was mortality. The secondary outcomes were mortality from 
cardiovascular causes, death from worsening heart failure, hospitalisation for worsening heart 
failure, and hospitalisation for other causes, in particular suspected digoxin toxicity. The 
composite outcome of cardiovascular death or heart failure hospitalisation was examined in the 
present study as a more contemporary endpoint in heart failure trials.10-13 
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2.3. Diabetes status 
The DIG trial was a large, simple, National Institutes of Health (NIH) funded study with 
limited biochemical investigations which did not include haemoglobin A1c (HbA1c) or 
fasting or non-fasting glucose.  Thus, a diagnosis of diabetes is based on a "Yes/No" 
checkbox under medical history in the study case report form. There were no specific 
diagnostic criteria for diabetes - the diagnosis was as reported by investigators.   
 
2.4. Statistical analysis  
We have full access to the annonymised individual patient’s data. Descriptive statistics were 
used to compare patients with and without diabetes. Data are presented as means (standard 
deviation [SD]) or medians (inter-quartile range [IQR]) for continuous variables and 
frequency (percent) for categorical variables. We examined the effect of randomised 
treatment on the following major clinical outcomes: the composite of cardiovascular (CV) 
death or heart failure (HF) hospitalisation (as the most commonly used composite in 
contemporary HF trials); the composite of HF death or HF hospitalisation (as pre-specified in 
the DIG trial protocol); the components of these composites; and all-cause death (the pre-
specified primary endpoint in the DIG trial protocol).  Comparison of clinical outcomes 
between study groups was performed using Kaplan-Meier estimates, with log-rank test, and a 
supportive Cox proportional-hazards regression model to calculate hazard ratios and 95% 
confidence intervals. The interaction between diabetes and the effect of treatment was also 
examined for each clinical outcome. The number of hospital admissions (taking account that 
individual patients had repeat admissions) in the study groups was evaluated using a negative 
binomial model. 
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We examined serum digoxin concentrations, creatinine and potassium in the study groups. 
We also explored the presence of hyperkalaemia or suspected digoxin toxicity (SDT) 
according to diabetes status (the latter adverse event was defined by and reported by the 
investigator). 
 
All analyses were undertaken using SAS version 9.3 (SAS Institute, Inc., Cary, NC, USA). 
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3. RESULTS 
Of the 6800 patients with heart failure and reduced ejection fraction (HF-REF) randomised in 
DIG, 1933 patients (28.4%) were reported by investigators to have diabetes (i.e. medical 
history of diabetes at baseline). 
 
3.1. Patients with and without diabetes 
Patients with diabetes were slightly older, more often women and had more symptoms and 
signs and worse NYHA functional class than those without diabetes (Table 1).  Patients with 
diabetes also had a higher average BMI, systolic blood pressure, heart rate and creatinine.  A 
history of coronary heart disease and hypertension was more common in individuals with 
diabetes compared to those without.  Diuretics were used more commonly in patients with 
diabetes compared to those without. 
 
3.2. Daily dose of digoxin 
Overall, the daily dose of digoxin taken was 0.125mg in 17.5%, 0.250mg in 70.6%, 0.375mg in 
10.3% and 0.500mg in 1.1% of patients (median daily dose 0.250 mg). In patients with diabetes, 
the daily dose of digoxin taken was 0.125 mg in 17.5%, 0.250 mg in 69.1%, 0.375 mg in 12.7% 
and 0.500 mg in 0.8%. In patient without diabetes, the daily dose of digoxin taken was 0.125 mg 
in 20.3%, 0.250 mg in 69.5%, 0.375 mg in 9.0% and 0.500 mg in 1.1%. The median daily dose 
for patients with diabetes and those without was the same (0.250 mg). 
 
3.3. Clinical outcomes 
The major clinical outcomes are shown in Table 2 and Figures 1-4. 
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3.3.1. Cardiovascular death or heart failure hospitalisation:  Overall, 1653 placebo treated 
patients (rate 20.6 per 100 patient years) and 1501 (rate 17.3) digoxin treated patients 
experienced the composite outcome of cardiovascular death or heart failure hospitalisation 
(hazard ratio 0.85, 95% CI 0.79-0.91; p<0.001).  The effect of digoxin on this outcome in 
patients with and without diabetes is shown in Table 2 and Figure 1.  Although the relative 
risk reduction with digoxin in patients with diabetes (10% [95%CI: -20 to +1%]) was 
numerically smaller than in those without diabetes (17% [-24 to -10%]), the test for 
interaction was not significant (p=0.27). 
 
3.3.2. Cardiovascular death:  Overall, 1004 placebo treated patients (rate 10.1 per 100 
patient years) and 1016 (rate 10.3) digoxin treated patients died from a cardiovascular death 
(HR 1.01, 95%CI: 0.93-1.11; p=0.782).  The effect of digoxin on this outcome in patients 
with and without diabetes is shown in Table 2 and Figure 2.  The lack of effect of digoxin on 
this outcome was similar, irrespective of diabetes status. 
 
3.3.3. Heart failure hospitalisation:  Overall, 1180 placebo treated patients (rate 14.7 per 100 
patient years) and 910 (rate 10.5) digoxin treated patients were hospitalised at least once for 
heart failure (HR 0.72, 95%CI: 0.66-0.79; p<0.001).  The effect of digoxin on this outcome in 
patients with and without diabetes is shown in Table 2 and Figure 3.  The relative risk 
reduction with digoxin in patients with diabetes (21%, 9 to 32%) was numerically smaller 
than in patients without diabetes (31%, 23 to 38%) although the test for interaction was not 
significant (p=0.14). 
Overall, there were 3046 hospital admissions (taking account of patients having more than 
one admission) in the placebo group and 2340 in the digoxin group (p<0.001).  In patients 
with diabetes these numbers were 1085 and 895, respectively (p=0.033) and in those without 
diabetes 1961 and 1445, respectively (p<0.001).  The incidence rate ratio (for digoxin 
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compared with placebo) in patients with diabetes was 0.88 (95%CI: 0.69-1.13) and 0.65 
(0.53-0.80) in patients without diabetes.  
 
3.3.4. Heart failure death or heart failure hospitalisation:  Overall, 1291 placebo treated 
patients (rate 16.1 per 100 patient years) and 1041 (rate 12.0) digoxin treated patients 
experienced the composite outcome of heart failure death or heart failure hospitalisation 
(hazard ratio 0.75, 95% CI 0.69-0.82; p<0.001).  The effect of digoxin on this outcome in 
patients with and without diabetes is shown in Table 2 and Figure 4.  Although the relative 
risk reduction with digoxin in patients with diabetes 20% (95% CI, 8 to 30%) was 
numerically smaller than in those without diabetes 27% (19 to 34%), the test for interaction 
was not significant (p=0.30). 
 
3.3.5. All-cause death:  Overall, 1194 placebo treated patients (rate 12.1 per 100 patient 
years) and 1181 (rate 11.9) digoxin treated patients died from all-cause death (HR 0.99, 95% 
CI 0.91-1.07; p=0.801).  The effect of digoxin on this outcome in patients with and without 
diabetes is shown in Table 2.  The lack of effect of digoxin on this outcome was similar, 
irrespective of diabetes status. 
 
3.4. Serum digoxin concentration, potassium and creatinine 
Serum digoxin concentrations were similar in patients with and without diabetes, in keeping 
with the similar daily dose of digoxin taken in the two groups as reported above (Table 3).  
Potassium concentrations were similar in patients with and without diabetes and in patients 
treated with placebo and those treated with digoxin. 
Serum creatinine concentrations were higher in patients with diabetes compared to those 
without diabetes (at both 1 month and 12 months).  Serum creatinine concentrations were 
markedly higher in patients experiencing digoxin toxicity irrespective of diabetes status. 
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3.5. Hyperkalaemia and suspected digoxin toxicity 
The proportion of patients with hyperkalaemia and suspected digoxin toxicity in patients with 
and without diabetes are shown in Table 4. The incidence of mild hyperkalaemia (serum 
potassium ≥5.5 mmol/l) was higher in patients with than without diabetes; the rate of more 
severe hyperkalaemia (serum potassium >6.0mmol/l) was low overall and similar in patients 
with and without diabetes. Hyperkalaemia appeared to be slightly more common in patients 
treated with digoxin compared to those treated with placebo. 
Suspected digoxin toxicity was more common in digoxin treated than in placebo treated 
patients. Suspected digoxin toxicity in patients randomised to digoxin was more common 
among patients with diabetes than without (6.5% versus 5.8%), as was hospitalisation for 
digoxin toxicity (1.4% versus 0.8%). 
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4. DISCUSSION 
As confirmed in the present report, heart failure patients with diabetes have more co-
morbidity, worse functional status and much higher rates of adverse outcomes than patients 
without diabetes.1-5   
 
The main benefit of digoxin was to reduce hospitalisation for heart failure.  This effect was 
numerically but not statistically significantly smaller in patients with diabetes compared to 
those without.  However, as the rate of heart failure hospitalisation was much higher in 
patients with diabetes, even the possibly smaller relative benefit of digoxin was still 
substantial.  Indeed, the absolute benefit in patients with diabetes (4.5 fewer patients admitted 
at least once per 100 patient years of treatment) was similar to those without diabetes (4.0 
fewer patients per 100 patient years).  For the composite of heart failure death or heart failure 
hospitalisation, these absolute risk reductions were 4.6 and 3.8 per 100 patient years of 
treatment, respectively.  Importantly, digoxin reduced repeat as well as first admissions and 
this benefit too was observed in patients with diabetes as well as in those without.  For every 
1000 patients with diabetes treated with digoxin, there were 182 fewer hospital admissions 
(including repeat admissions) over the average duration of follow-up, compared with 
placebo.  The comparable number for patients without diabetes was 214 admissions.  These 
data suggest that digoxin has the potential to provide substantial, clinically meaningful 
benefits, in patients with HF-REF and diabetes.  Of course, DIG was conducted before the 
demonstration of the value of mineralocorticoid receptor antagonists (MRAs) and beta-
blockers (and devices) in HF-REF and whether the same incremental benefits can be obtained 
in patients taking these two treatments as well as an ACE inhibitor is unknown. 
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The other important consideration is the tolerability of digoxin in patients with diabetes.  
Patients with diabetes are more likely to have renal dysfunction, as demonstrated in the 
present analysis.  Reduced renal clearance increases the risk of digoxin toxicity.  Despite this, 
and the relatively high dose of digoxin used in DIG, the risk of digoxin toxicity was low 
although patients who experienced digoxin toxicity had a higher average serum creatinine at 
that time (compared with other patients) and suspected digoxin toxicity was more slightly 
common in patients with diabetes than without. 
 
Although the DIG trial was conducted more than 20 years ago, it remains the only large, 
prospective, randomized, placebo-controlled outcome trial with digoxin in patients with heart 
HF-REF. As such, it continues to inform all major international heart failure guidelines. 
Consequently, it remains the most robust source of information on the effects of digoxin in 
HF-REF patients with and without diabetes. Given that HF-REF patients with diabetes have 
generally more severe symptoms than patients without diabetes, they will also have a more 
frequent indication for digoxin according to current guidelines (where digoxin is particularly 
indicated in patients with persisting or more severe symptoms despite other recommended 
therapy). As a result, we believe that our findings still have contemporary relevance. Indeed, 
a recent systematic review of 52 clinical trials and observational studies demonstrated that 
individuals treated with digoxin were more likely to have diabetes than those not treated with 
digoxin and confirmed in a much larger population the lack of mortality risk with digoxin 
observed in the DIG trial.14  
 
In another analysis of the DIG trial, including the 988 patients in the ancillary study with a 
LVEF >45%, cluster analysis suggested that digoxin treatment may be associated with a 
higher mortality in patients with a heart failure with preserved ejection fraction (HF-PEF) 
phenotype (including older age higher LVEF and systolic blood pressure, female sex and 
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history of diabetes).15 Consequently, we do not know whether our findings with respect to the 
safety of digoxin in patients with HF-REF also apply to patients with HF-PEF. 
 
This report has a number of limitations. This is a retrospective analysis. DIG was conducted 
before the demonstration of benefit of several different drugs (including beta-blockers and 
MRAs) and devices. As with all trials, the patients enrolled were selected according to 
inclusion and exclusion criteria (as detailed in the Methods section). Suspected digoxin 
toxicity was investigator reported and not adjudicated or always confirmed by serum 
measurements. Thus, serum concentrations of digoxin, potassium and creatinine are available 
only for a part of the study cohort. Heart rate was not measured during follow-up. 
 
In summary, when added to an ACE inhibitor digoxin reduces heart failure hospitalisation in 
HF-REF patients with and without diabetes without any major off-setting toxicity.  Although 
the relative risk reduction in patients with diabetes may be somewhat smaller than in 
individuals without diabetes, the absolute risk reduction remains substantial (because the 
absolute rate of adverse outcomes is much higher in patients with diabetes). 
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FIGURES LEGENDS 
 
Figure 1: Kaplan Meier cumulative risk of the composite outcome of CV death or HF 
hospitalisation in patients with and without diabetes. 
 
Figure 2: Kaplan Meier cumulative risk of CV death in patients with and without diabetes.  
 
Figure 3: Kaplan Meier cumulative risk of HF hospitalisation in patients with and without 
diabetes. 
 
Figure 4: Kaplan Meier cumulative risk of the composite outcome of HF death or HF 
hospitalisation in patients with and without diabetes.  
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TABLES 
Table 1. Baseline characteristics according to diabetes status at baseline. 
 
All patients 
(N= 6800) 
Without 
Diabetes  
(n= 4867) 
With 
Diabetes  
(n= 1933) 
Demographics, n (%)    
Age, year 63.5 ± 10.9 63.2 ± 11.5* 64.2 ± 9.3* 
Caucasians 5809 (85.4) 4218 (86.7)* 1591 (82.3)* 
Female sex 1519 (22.3) 1008 (20.7)* 511 (26.4)* 
NYHA class  
I 907 (13.3) 699 (14.4)* 208 (10.8)* 
II 3664 (53.9) 2689 (55.3)* 975 (50.4)* 
III 2081 (30.6) 1392 (28.6)* 689 (35.6)* 
IV 142 (2.1) 83 (1.7)* 59 (3.1)* 
Duration of heart failure, year    2.5 ± 3.1 2.5 ± 3.1 2.5 ± 3.1 
LV Ejection Fraction, % 28.5 ± 8.9 28.3 ± 9.0* 29.1 ± 8.6* 
Cardiothoracic ratio 0.53 ± 0.1 0.53 ± 0.1* 0.54 ± 0.1* 
No. of signs or symptoms of CHF†    
0 73 (1.1) 60 (1.2)* 13 (0.7)* 
1 149 (2.2) 117 (2.4)* 32 (1.7)* 
2 483 (7.1) 389 (8.0)* 94 (4.9)* 
3 607 (8.9) 465 (9.6)* 142 (7.4)* 
≥4 5486 (80.7) 3834 (78.8)* 1652 (85.5)* 
 
Baseline vital signs    
BMI, kg/m2 27.1 ± 5.2 26.5 ± 5.0* 28.6 ± 5.5* 
BP, mmHg    
Systolic 125.8 ± 19.9 124.6 ± 19.7* 128.8 ± 20.3* 
Diastolic 74.9 ± 11.3 75.0 ± 11.3* 74.8 ± 11.2* 
Heart rate, beats/min 78.8 ± 12.7 77.8 ± 16.9* 81.2 ± 12.3* 
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All patients 
(N= 6800) 
Without 
Diabetes  
(n= 4867) 
With 
Diabetes  
(n= 1933) 
Laboratory measurements 
Potassium, mmol/L, median (IQR)  4.3 (4.1-4.6) 4.3 (4.0-4.6)* 4.4 (4.1-4.7)* 
Serum creatinine, µmol/L    113.4 ± 32.6 112.0 ± 30.9* 117.1 ± 36.2* 
Medical history, n (%)    
Myocardial Infarction 4419 (65.0) 3126 (64.2)* 1293 (66.9)* 
Angina 1821 (26.8) 1248 (25.6)* 573 (29.6)* 
Hypertension 3084 (45.4) 1971 (40.5)* 1113 (57.6)* 
Previous digoxin use 3017 (44.4) 2149 (44.2) 868 (44.9) 
 
Medication, n (%) 
 
Potassium-sparing diuretic 517 (7.6) 367 (7.5) 150 (7.8) 
Other diuretics 5325 (78.3) 3688 (75.8)* 1637 (84.7)* 
ACE inhibitor  6422 (94.4) 4587 (94.3) 1835 (94.9) 
Nitrate  2898 (42.6) 1896 (39.0)* 1002 (51.8)* 
Hydralazine 141 (2.1) 74 (1.5)* 67 (3.4)* 
    
Randomised to digoxin 3397 (50.0) 2436 (50.1) 961 (49.7) 
 
All continous values are given in mean ± standard deviation unless stated otherwise. CHF: 
chronic heart failure;  n(%): number of observations (percentage of observations within the 
group); NYHA: New York Heart Association; BMI: body mass index; ACE: angiotensin 
converting enzyme; LV: left ventricle; IQR: interquartile range; DIG: Digitialis Investigation 
Group. 
† The clinical signs or symptoms studied included rales, elevated jugular venous pressure, 
peripheral oedema, dyspnoea at rest or on exertion, orthopnoea, limitation of activity, S3 
gallop and radiological evidence of pulmonary congestion. 
* Significant difference, p<0.05.
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Table 2. Clinical outcomes according to diabetes status and randomised treatment assignment. 
 
 No diabetes Diabetes  
 Placebo 
(n=2431) 
Digoxin 
(n=2436) 
HR 
(95% CI) 
Placebo 
(n=972) 
Digoxin 
(n=961) 
HR  
(95% CI) 
p-value for 
interaction 
CV death or HF hospitalisation, n (rate*) 1086 (18.2) 966 (14.9) 0.83 (0.76,0.90) 567 (27.6) 535 (24.6) 0.90 (0.80,1.01) 0.27 
CV death, n (rate) 664 (9.2) 665 (9.2) 0.99 (0.89,1.11) 340 (12.6) 351 (13.3) 1.06 (0.92,1.24) 0.47 
HF hospitalisation, n (rate) 760 (12.7) 563 (8.7) 0.69 (0.62,0.77) 420 (20.5) 347 (16.0) 0.79 (0.68,0.91) 0.14 
HF death or HF hospitalisation, n (rate) 831 (13.9) 654 (10.1) 0.73 (0.66,0.81) 460 (22.4) 387 (17.8) 0.80 (0.70,0.92) 0.30 
HF death, n (rate) 288 (4.0) 256 (3.5) 0.88 (0.75,1.04) 161 (5.9) 138 (5.2) 0.89 (0.71,1.12) 0.98 
 
All-cause death, n (rate) 790 (11.0) 772 (9.9) 0.97 (088,1.07) 460 (14.9) 387 (15.5) 1.04 (0.91,1.20) 0.40 
* per 100 patient-years. CV = cardiovascular. HF = heart failure 
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Table 3. Serum concentrations of digoxin, potassium and creatinine. 
 
Blood 
parameters 
Timeline Without diabetes With diabetes 
Placebo Digoxin Placebo Digoxin 
Serum digoxin* 
(ng/mL) 
1M† ‡  0.8 ± 0.5  0.9 ± 0.5 
12M† | |  0.8 ± 0.5  0.8 ± 0.5 
SDT ª  1.1 ± 0.9  1.2 ± 0.8 
Potassium 
(mmol/L) 
1M§ 4.4 ± 0.5 4.4 ± 0.5 4.5 ± 0.5 4.5 ± 0.5 
12M# 4.4 ± 0.5 4.4 ± 0.5 4.4 ± 0.5 4.5 ± 0.4 
SDTb 4.2 ± 0.4 4.4 ± 0.6 4.5 ± 0.7 4.5 ± 0.8 
Serum creatinine 
(umol/L) 
1M ȸ 115.3 ± 37.5 109.9 ± 33.7 119.7 ± 38.8 115.1 ± 36.5 
12M** 115.9 ± 37.7 113.5 ± 33.6 129.1 ± 58.4 120.4 ± 48.8 
SDTc 113.9 ± 35.8 137.5 ± 51.9 162.9 ± 44.5 172.8 ± 91.8 
 
1M indicates 1-month visit; 12M: 12-month visit; SDT: suspected digoxin toxicity. Values are given in 
mean ± standard deviation. 
* Digoxin concentration for patients who received digoxin or patient with suspected digoxin toxicity 
during the trial. 
† Blood samples obtained 6 hours after the last dose. 
‡ Data available for 1497 patients (1084 without diabetes and 413 with diabetes). 
§ Data available for 1608 patients (1140 without diabetes and 468 with diabetes). 
| | Data available for 1294 patients (957 without diabetes and 337 with diabetes). 
# Data available for 1036 patients (770 without diabetes and 266 with diabetes). 
ȸ Data available for 1616 patients (1144 without diabetes and 472 with diabetes). 
** Data available for 1036 patients (770 without diabetes and 266 with diabetes). 
ª Data available for 222 patients (156 without diabetes and 66 with diabetes). 
b Data 102 patients (77 without diabetes and 25 with diabetes). 
c Data 104 patients (79 without diabetes and 25 with diabetes). 
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Table 4. Proportions of patients with hyperkalaemia or suspected digoxin toxicity (SDT) according to 
diabetes status. 
Events Timeline Without diabetes, n(%) With diabetes, n(%) 
Placebo Digoxin Placebo Digoxin 
Hyperkalaemia,  
K+ ≥ 5.5mmol/L 
1M* 8 (0.7) 11 (1.0) 11 (2.3) 8 (1.7) 
12M† 5 (0.6) 9 (1.2) 3 (1.1) 4 (1.5) 
SDT‡ 0 (0.0) 1 (1.3) 2  (8.0) 2 (8.0) 
Hyperkalaemia,  
K+ > 6.0mmol/L 
1M* 2 (0.2) 7 (0.6) 1  (0.2) 3 (0.6) 
12M† 2 (0.3) 4 (0.5) 0 (0.0) 2 (0.8) 
SDT‡ 0 (0.0) 1 (1.3) 0 (0.0) 0 (0.0) 
SDT§  191 (3.9) 280 (5.8) 79 (4.1) 126 (6.5) 
Hospitalisation due to 
SDT 
 20 (0.4) 40 (0.8) 11 (0.6) 27 (1.4) 
 
1M indicates 1-month visit; 12M: 12-month visit; SDT: suspected digoxin toxicity. Values are given in 
‘number (percentage)’ format. 
* Data available for 1608 patients (1140 without diabetes and 468 with diabetes). 
† Data available for 1036 patients (770 without diabetes and 266 with diabetes). 
‡ Data available for 102 patients (77 without diabetes and 25 with diabetes). 
§ Data available for 6800 patients (4867 without diabetes and 1933 with diabetes). 
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